Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene FLT3
Variant I836T
Impact List missense
Protein Effect gain of function - predicted
Gene Variant Descriptions FLT3 I836T lies within the protein kinase domain of the Flt3 protein (UniProt.org). I836T results in IL3-independent growth in culture (PMID: 28077790), and therefore, is predicted to lead to a gain of Flt3 protein function.
Associated Drug Resistance
Category Variants Paths

FLT3 mutant FLT3 act mut FLT3 I836T

FLT3 mutant FLT3 exon20 FLT3 I836X FLT3 I836T

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_004119.2
gDNA chr13:g.28018501A>G
cDNA c.2507T>C
Protein p.I836T
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_004119.2 chr13:g.28018501A>G c.2507T>C p.I836T RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FLT3 I836T hematologic cancer no benefit Crenolanib Preclinical - Cell culture Actionable In a preclinical study, Crenolanib (CP-868596) did not inhibit viability of transformed cells expressing FLT3 I836T in culture (PMID: 28077790). 28077790
FLT3 I836T hematologic cancer sensitive Lestaurtinib Preclinical - Cell culture Actionable In a preclinical study, Lestaurtinib (CEP-701) inhibited Flt3 autophosphorylation and viability in transformed cells expressing FLT3 I836T in culture (PMID: 28077790). 28077790
FLT3 I836T hematologic cancer sensitive Linifanib Preclinical - Cell culture Actionable In a preclinical study, Linifanib (ABT-869) inhibited viability in transformed cells expressing FLT3 I836T in culture (PMID: 28077790). 28077790
FLT3 I836T hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) inhibited Flt3 autophosphorylation and viability in transformed cells expressing FLT3 I836T in culture (PMID: 28077790). 28077790
FLT3 I836T hematologic cancer no benefit Ponatinib Preclinical - Cell culture Actionable In a preclinical study, Iclusig (ponatinib) did not inhibit viability of transformed cells expressing FLT3 I836T in culture (PMID: 28077790). 28077790
FLT3 I836T hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) inhibited viability in transformed cells expressing FLT3 I836T in culture (PMID: 28077790). 28077790
FLT3 I836T hematologic cancer sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) inhibited viability in transformed cells expressing FLT3 I836T in culture (PMID: 28077790). 28077790
FLT3 I836T hematologic cancer sensitive Sunitinib Preclinical - Cell culture Actionable In a preclinical study, Sutent (sunitinib) inhibited viability in transformed cells expressing FLT3 I836T in culture (PMID: 28077790). 28077790
FLT3 I836T hematologic cancer no benefit AG1295 Preclinical - Cell culture Actionable In a preclinical study, AG1295 did not inhibit viability of transformed cells expressing FLT3 I836T in culture (PMID: 28077790). 28077790
FLT3 I836T hematologic cancer sensitive KW-2449 Preclinical - Cell culture Actionable In a preclinical study, KW-2449 inhibited viability in transformed cells expressing FLT3 I836T in culture (PMID: 28077790). 28077790